secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001453687-24-000122
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Q3 net loss $(24.2)M; cash $220.9M; Phase 3 Descartes-08 in MG expected 1H2025
--------------------------------------------------------------------------------

- Cash and equivalents $220.9M as of Sep 30, 2024; runway expected into mid-2027.
- Net loss $(24.2)M ($(1.13)/share) vs $(9.0)M ($(1.74)) in Q3 2023.
- Research and development expenses $11.4M, down from $13.0M year-over-year.
- Plan to commence Phase 3 trial of Descartes-08 in myasthenia gravis in 1H2025 after FDA meeting.
- Completed $130M PIPE financing in July 2024; first patient dosed in Phase 2 SLE trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000122/0001453687-24-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000122/rnac-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer